GLP1R and medullary thyroid gland carcinoma: GLP-1 RA preclinical rodent studies demonstrate an increase in thyroid C-cell neoplasm occurrence which has led to a Food and Drug Administration black box warning.35 Consequently, these agents are contraindicated in patients with a personal or family history of medullary thyroid cancer or those diagnosed with multiple endocrine neoplasia syndrome type 2.